50DMA will cross 200DMA to the upside, an event tomorrow or Thursday will trigger it. You don't want to be short when that happens.
The market has an uncanny way of leaking news into a chart. Take a look at what is about to happen with the 50 and 200 DMA. Something is brewing. If the chart shows what I think it does, we're about to see a significant one day move upwards of 45-60%.
Tell me you're not short with Phase 3 approval pretty much a sure thing? Remember, this drug is already approved in the EU.
It's a fact, look it up. And that's were this is headed... greater than $300m marketcap as approval is all but a sure thing given Biomarin is already selling Firdapse in Europe. That puts CPRX at or greater than $4.50 a share simply based on positive phase 3 results. Approval probably adds another $300m - $400m to the marketcap later this year. This is easily a $9-10 stock on approval, that's if Biomarin doesn't buy them before that.
What's a reasonable offer? 800m-1b Market Cap?
Good point. Doctors either know it's working or not. Given recent volume and increasing institutional ownership I think we have out answer. Thanks.
Recall the $1.9 Million Dollar Fast Track Grand from NIH. Data coming in a few weeks, and given the recent volume plus institutional ownership... Baker Bros, FMR, Broadfin, Millennium, the data is likely positive. Uptrend into data has started. Positive data brings us to $8.
"This study is as an escalating dose study evaluating three dose levels of aerosolized KL4 surfactant and is expected to be completed in the third quarter of 2014."
CUR = CURE. That's what they are shooting for. No other company is even close. If you disagree show me another company this far along towards beating ALS.
Seriously, it's one thing to give an experimental drug to someone. It doesn't take much for a nurse to hook them up to an IV and see what happens, it's another whole ballgame to book an OR, all the associated support staff, and perform a massively invasive procedure on someone's C-Spine. You only do that, if the return exceeds the risk. Given these procedures are continuing to happen at the aforementioned hospitals tells me the researchers and surgeons must believe they are helping patients. To me that suggests NSI-566 is the only possible cure for ALS in the works. Investors just haven't figured that out yet. I'd like to know if any other Biotechs are this far along?
Thanks I just looked at BCLI, they don't seem on par with Neuralstem. For me, what's most interesting about Neuralstem's trials in ALS is that they are being conducted at Emory, UMichigan, and Mass General. For those research hospitals to commit resources and training to operative ALS procedures suggests to me that CUR is in a class all its own. Those are big names putting their reputation behind NSI-566. Not to mention the Neurosurgeons performing these procedures. Agree?
Can anyone point me at other companies that are in any serious active trials for ALS? It would seem to me that Neuralstem will likely end up with the first approved ALS treatment making this stock a tremendous value at todays price. I'm curious if other agree/disagree. Thanks.
No other choice.
I bet the majority of people on this board don't even realize this. I verified it two weeks ago and bought shares then knowing this was easy $$$. Tekmira is the only company with an ongoing FDA trial. I challenge anyone to prove otherwise.
The less Tekmira says the more you know there is material non public discussions happening with the FDA. This stock easily will see $75-$100 a share this week.
Go the the FDA clinical trial website and punch in Ebola. Tekmira is the only company listed with an Ebola drug trial. No other pharmaceutical company is listed - none! Not Glaxo or Mapp. This is the real deal. Go verify it yourself.